Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc-99m-tilmanocept Imaging in Advanced Melanoma
NCT04663126Phase 1Terminated
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of technetium tc 99m tilmanocept in melanoma. Primary endpoint: Imaging results. Started Feb 2021; status: terminated.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04663126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04663126.